（编辑 王雪儿） 证券日报网讯 12月5日，盈康生命在互动平台回答投资者提问时表示，公司始终高度重视市值管理，并 坚持在聚焦主业、提升经营效率和盈利能力的基础上，综合运用包括增持回购、股权激励、非公开发行 股票、并购等方式系统性地强化市值管理与投资者回报。2025年，公司审议通过了旨在完善治理与回报 机制的相关制度。外延发展方面，公司于2025年上半年完成对长沙珂信肿瘤医院51%股权的收购，旨在 进一步夯实在医疗服务领域的肿瘤特色，增厚业绩并增强持续经营能力。此外，公司始终致力于提升规 范运作与信息披露质量，以有效传递公司价值。 ...

Group 1 - The core point of the article is that Yingkang Life plans to acquire a 51% stake in Changsha Kexin Oncology Hospital for 357 million yuan, which will allow it to gain control and consolidate the hospital's financials [2] - Changsha Kexin, established in 2015, is a tertiary oncology specialty hospital with 420 beds and reported revenue of 273 million yuan and net profit of 33.43 million yuan for the first three quarters of 2024 [2] - The hospital has committed to achieving net profits of no less than 57 million yuan, 58 million yuan, and 60 million yuan for the years 2025 to 2027, totaling 175 million yuan, which represents a significant increase of 73%-82% compared to historical performance [2] Group 2 - The acquisition is part of Yingkang Life's "1+n" strategy, which aims to establish a regional center hospital that supports multiple satellite hospitals [2] - Currently, Yingkang Life operates three owned hospitals and seven managed institutions, with projected medical service revenue of 1.192 billion yuan in 2024, where oncology revenue is expected to account for 31.9% [3] - Following the acquisition, Yingkang Life's total assets are reported at 3.537 billion yuan, with a debt ratio of 29.93%, indicating that total liabilities may increase post-acquisition [3]

Core Viewpoint - Yingkang Life announced the acquisition of 51% equity in Changsha Kexin Oncology Hospital for 357 million yuan, with an overall valuation of approximately 700 million yuan, resulting in a premium rate of 1429.99%, significantly exceeding the average merger premium in the healthcare industry [1][2] Group 1: Acquisition Details - The acquisition price of 357 million yuan corresponds to Changsha Kexin's net assets of 46.14 million yuan as of September 2024, indicating a high premium rate [1] - The acquisition will create approximately 280 million yuan in goodwill, accounting for 78% of the purchase price [2] Group 2: Financial Performance and Risks - Changsha Kexin has committed to net profits of 57 million, 58 million, and 60 million yuan for the years 2025 to 2027, respectively, but has only achieved a net profit of 33.42 million yuan in the first three quarters of 2024, indicating challenges in meeting these targets [2] - The realization of these profit commitments is dependent on uncontrollable factors such as local medical insurance policies and competition from public hospitals, which adds uncertainty to the performance outlook [2] Group 3: Historical Context and Concerns - Yingkang Life has previously faced issues with high premium acquisitions, such as the 2015 acquisition of Maxip, which resulted in 947 million yuan in goodwill and 804 million yuan in impairments by 2021 [3] - High premium acquisitions lead to increased goodwill on the balance sheet, which is essentially a prepayment for the future profitability of the acquired entity; if performance does not meet expectations, goodwill impairment will directly impact the company's profits [3] Group 4: Strategic and Operational Challenges - The strategic synergy of the acquisition is questionable, as Yingkang Life's core competencies lie in medical device R&D and oncology treatment technology, while Changsha Kexin operates as a regional hospital reliant on localized medical services [4] - The acquisition may dilute core business resources, as the high cash outflow could affect the development of key projects like high-end imaging equipment and AI diagnostic algorithms, leading to a diversion of management focus [4] - The regional oncology market is highly competitive, with public hospitals attracting patients away from private facilities, making it difficult for Changsha Kexin to maintain its market position [5]

Core Insights - The company reported a revenue of 1.559 billion yuan for the fiscal year 2024, marking a year-on-year growth of 6.01%, and a net profit attributable to shareholders of 115 million yuan, reflecting a year-on-year increase of 14.92% [1] - The company announced plans to acquire 51% of Changsha Kexin Tumor Hospital for 357 million yuan, indicating ongoing expansion in the medical services sector [2] Financial Performance - The company's Q4 revenue for 2024 was 332 million yuan, showing a decline of 9.76% year-on-year, while the net profit for the same period was 33 million yuan, a significant increase of 415.24% [3] - For the full year 2024, the medical services revenue was 1.192 billion yuan, up 3.76% year-on-year, with a five-year CAGR of 27%, while the medical device revenue reached 367 million yuan, up 14.05% year-on-year, with a five-year CAGR of 16% [3] Acquisition Details - The target hospital, Changsha Kexin Tumor Hospital, reported revenues of 263 million yuan and 273 million yuan for 2023 and Q1-Q3 2024 respectively, with net profits of 32.93 million yuan and 33.43 million yuan, and net profit margins of 12.5% and 12.3% [3] - The acquisition includes performance commitments for the years 2025-2027, with expected net profits of 57 million, 58 million, and 60 million yuan respectively, and a cumulative net profit threshold of 175 million yuan [3] Investment Outlook - The company is expected to achieve revenues of 1.821 billion, 2.114 billion, and 2.308 billion yuan for the years 2025-2027, representing year-on-year growth rates of 16.8%, 16.1%, and 9.2% respectively [4] - The projected net profits for the same period are 136 million, 161 million, and 188 million yuan, with year-on-year growth rates of 18.1%, 18.4%, and 16.5% [4]